Cost-effectiveness of rotavirus vaccination in Kenya and Uganda

Vaccine

Volumn 33, Issue S1, 2015, Pages A109-A118

  Sigei, Charles ^a   Odaga, John ^b,c   Mvundura, Mercy ^d   Madrid, Yvette ^e   Clark, Andrew David ^f   Mutie, Dominic ^a   Kamau, Peter ^a   Mungai, Amina Ishmael ^a   Watiri, Terry ^a   Gatheru, Zipporah ^a   Charo, Joyce ^a   Osano, Bonface ^a   Mwinyi, Bakari ^a   Kamenwa, Rose ^a   Nyangoa, J ^a   KennedyChitala, ^a   Muitherero, Charles ^a   Koskei, Nancy ^a   Omurwa, Tom ^a   Murunga, Peninah ^a   Mayanja, Robert ^a   Aanyu, Hellen ^a   Mugisha, David ^a   Mulindwa, Augustine ^a   Nalumansi, Esther ^a   Kisakye, Annet ^a   Henry, Luzze ^a   Lochoro, Peter ^a   Bwogi, Josephine ^a   Walimbwa, Aliyi ^a   Robinson, E Edward ^a   Ruhambarama, Jolly ^a   more..

^a PO Box 293 20203 ^*

^b UGANDA MARTYRS UNIVERSITY   (Uganda)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^d PATH   (United States)

^e PATH   (Switzerland)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cost effectiveness analysis; DALYs; Kenya; Rotavirus; TRIVAC; Uganda; Vaccination

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CHILD; CHILDHOOD MORTALITY; COHORT ANALYSIS; CONSULTATION; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DISABILITY; DISABILITY ADJUSTED LIFE YEAR; DRUG COST; GOVERNMENT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HUMAN; KENYA; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SECONDARY ANALYSIS; UGANDA; VACCINATION; VALIDATION STUDY; VIRUS LOAD; COST BENEFIT ANALYSIS; ECONOMICS; GASTROENTERITIS; HEALTH CARE POLICY; IMMUNOLOGY; INFANT; NEWBORN; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; PROCEDURES; ROTAVIRUS INFECTIONS; STATISTICAL MODEL;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; GASTROENTERITIS; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; KENYA; MODELS, STATISTICAL; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; UGANDA; VACCINATION;

EID: 84928626302     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.12.079     Document Type: Article

References (45)

1. World Health Organization. Children Children: reducing mortality. Fact sheet 178. Available at: [accessed 25.03.14]. http://www.who.int/mediacentre/factsheets/fs178/en/.
2. Kotloff K.L., Nataro J.P., Blackwelder W.C., Nasrin D., Farag T.H., Panchalingam S., et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013, 382(9888):209-222.
3. Lanata C.F., Fischer-Walker C.L., Olascoaga A.C., Torres C.X., Aryee M.J., Black R.E. Global causes of diarrheal disease mortality in children <5 years of age: a systematic review. PLoS ONE 2013, 8(9):e72788. Child Health Epidemiology Reference Group of the World Health Organization and UNICEF.
4. Walker C.L., Aryee M.J., Boschi-Pinto C., Black R.E. Estimating diarrhea mortality among young children in low and middle income countries. PLoS ONE 2012, 7(1):e29151.
5. World Health Organization. 2008 rotavirus deaths, under 5 years of age, as of 31 January 2012. Available at: [accessed 30.04.14]. http://www.who.int/immunization/monitoring_surveillance/burden/estimates/rotavirus/ChildRota2008.xls.
6. Mwenda M., Ntoto K., Abebe A., Enweronu-Laryea C., Amina I., Mchomvu J., et al. Burden and epidemiology of rotavirus diarrhea in selected African Countries: preliminary results from the African rotavirus surveillance network. J Infect Dis 2010, 202(1):S5-S11.
7. World Health Organization Rotavirus vaccines: WHO position paper - January 2013. Wkl Epidemiol Rec 2013, 5(88):49-64. Available at: www.who.int/wer/2013/wer8805.pdf [accessed 26.03.14].
8. Boom J.A., Tate J.E., Sahni L.C., Rench M.A., Hull J.J., Gentsch J.R., et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2010, 125:e199-e207.
9. Toscano C.M., Jauregui B., Janusz C.B., Sinha A., Clark A.D., Sanderson C., et al. Establishing a regional network of academic centers to support decision-making for new vaccine introduction in Latin America and the Caribbean: the ProVac experience. Vaccine 2013, 31(Suppl. 3):C12-C18.
10. Clark A., Jauregui B., Griffiths U., Janusz C.B., Bolaños-Sierra B., Hajjeh R., et al. TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination. Vaccine 2013, 31(3):C19-C29.
11. WHO-CHOICE Choosing interventions that are cost-effective (CHOICE): quantities and unit prices 2008, Available at http://www.who.int/choice/cost-effectiveness/inputs/en/.
12. Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J., Stoddart G.L. Methods for the economic evaluation of health care programmes 2005, Oxford University Press, Oxford, United Kingdom. 3rd ed.
13. United Nations, Department of Economic and Social Affairs, Population Division World Population Prospects: the 2012 Revision, DVD Edition 2013, UN Population Division, New York, Available at: http://esa.un.org/unpd/wpp/Excel-Data/population.htm [accessed 24.03.14].
14. World Health Organization. WHO/UNICEF Joint Reporting Process. Available at: [accessed 24.03.14]. http://www.who.int/immunization/monitoring_surveillance/routine/reporting/reporting/en/.
15. van Hoek A.J., Ngama M., Ismail A., Chuma J., Cheburet S., Mutonga D., et al. A cost-effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya: comparison between Rotarix and RotaTeq vaccines. PLoS ONE 2012, 7(10):e47511.
16. Tate J., Rheingans R., O'Reilly C., Obonyo B., Burton D.C., Tornheim J.A., et al. Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in Kenya. J Infect Dis 2009, 200(1):S76-S84.
17. Uganda Bureau of Statistics (UBOS) and ICF International Inc. Uganda Demographic and Health Survey 2011 2012, UBOS and Calverton/ICF International Inc, Kampala, Uganda/Maryland, Available at: http://213.154.74.164/invenio//record/18686/files/PR18.pdf [accessed 26.03.14].
18. Boschi-Pinto C., Lanata C.F., Mendoza W., Habte D. Diarrheal diseases. Chapter 9. Disease and mortality in Sub-Saharan Africa 2006, World Bank, Washington, DC, Available at: https://openknowledge.worldbank.org/bitstream/handle/10986/7050/363050Disease0101OFFICIAL0USE0ONLY1.pdf [accessed 26.03.14]. 2nd ed. D.T. Jamison, R.G. Feachem, M.W. Makogaba (Eds.).
19. Uganda Ministry of Health District Health Information System 2: Uganda Electronic Health Information System 2013, Available at: http://hmis2.health.go.ug/ [accessed 28.02.14].
20. Sanderson C. WHO IVR Schedule report. Immunizing children against rotavirus: making the most of every contact 2013, Available at: http://www.vaccine-schedules.com/country-reports/ [accessed 28.02.14].
21. Uganda, Mulago National Referal Hospital Unpublished data.
22. World Health Organization Global Burden of Disease (GBD) Project Global burden of disease (GBD) web page 1990, Available at: www.who.int/healthinfo/global_burden_disease/about/en/ [accessed 26.03.14].
23. Clark A., Sanderson C. Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data. Lancet 2009, 373(9674):1543-1549.
24. World Health Organization. Uganda: WHO and UNICEF estimates of immunization coverage: 2012 revision. Available at: [accessed 26.03.14]. http://www.who.int/immunization/monitoring_%20surveillance/data/uga.pdf.
25. World Health Organization. Kenya: WHO and UNICEF estimates of immunization coverage: 2012 revision. Available at: . http://www.who.int/immunization/monitoring_%20surveillance/data/ken.pdf.
26. Salinas B., Pérez Schael I., Linhares A.C., Ruiz Palacios G.M., Guerrero M.L., Yarzábal J.P., et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005, 24(9):807-816.
27. Patel M.M., Clark A.D., Sanderson C., Tate J., Parashar U.D. Removing the age restrictions for rotavirus vaccination: a benefit-risk modeling analysis. PLoS Med 2012, 9(10):e1001330.
28. de Palma O., Cruz L., Ramos H., de Baires A., Villatoro N., Pastor D., et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. Br Med J 2010, 340:c2825.
29. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362(4):289-298.
30. Griffiths U., Korczak V., Ayalew D., Yigzaw A. Incremental system costs of introducing combined DTwP-hepatitis B-Hib vaccine into national immunization services in Ethiopia. Vaccine 2009, 27(9):1426-1432.
31. Flessa S., Moeller M., Ensor T., Hornetz K. Basing care reforms on evidence: the Kenya health sector costing model. BMC Health Serv Res 2011, 11:128.
32. Kenya Ministry of Health Household Health Expenditure and Utilisation Survey Report 2007, Available from: http://www.ihpmr.org/wp-content/uploads/2012/10/Household-Health-Expenditure-Survey-Report-2007_FINAL-DRAFT_30-Jan-09_edLM.pdf.
33. Uganda Ministry of Health The Cost of Services in Various Referral Levels of Public Facilities (HCs III, IV, and V). Consultancy report prepared for the Uganda Ministry of Health 2008.
34. Uganda Ministry of Health The Cost of Specific Health Services at Selected Private-for-Profit Hospitals. Consultancy report prepared for the Uganda Ministry of Health 2008.
35. Tate J., Kisakye A., Mugyeni P., Kizza D., Odiit A., Braka F. Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda. Vaccine 2011, 29(17):3329-3334.
36. Clark A.D., Walker D.G., Mosqueira N.R., Penny M.E., Lanata C.F., Fox-Rushby J., et al. Cost-effectiveness of rotavirus vaccination in Peru. J Infect Dis 2009, 200(Suppl. 1):S114-S124.
37. Constenla D., Velázquez F.R., Rheingans R.D., Antil L., Cervantes Y. Economic impact of a rotavirus vaccination program in Mexico. Rev Panam Salud Publica 2009, 25(6):481-490.
38. Berry S.A., Johns B., Shih C., Berry A.A., Walker D.G. The cost-effectiveness of rotavirus vaccination in Malawi. J Infect Dis 2010, 202(Suppl.):S108-S115.
39. Kim S.Y., Sweet S., Slichter D., Goldie S.J. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Public Health 2010, 10:253.
40. Atherly D.E., Lewis K.D., Tate J., Parashar U.D., Rheingans R.D. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030. Vaccine 2012, 30(Suppl. 1):A7-A14.
41. Abbott C., Tiede B., Armah G., Mahmoud A. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana. Vaccine 2012, 30(15):2582-2587.
42. Liu N., Yen C., Fang Z.Y., Tate J.E., Jiang B., Parashar U.D., et al. Projected health impact and cost-effectiveness of rotavirus vaccination among children <5 years of age in China. Vaccine 2012, 30(48):6940-6945.
43. Rheingans R., Anderson J.D., Anderson B., Chakraborty P., Atherly D., Pindolia D. Estimated impact and cost-effectiveness of rotavirus vaccination in India: effects of geographic and economic disparities. Vaccine 2014, 32(Suppl. 1):A140-A150.
44. Out of pocket expenditure as a percentage of total health expenditure, H.E.I., WHO Global Health Expenditure Database, available at . http://apps.who.int/nha/database.
45. UNICEF Supplies and Logistics Vaccine Price Data. Available at . http://www.unicef.org/supply/index_57476.html.